Last reviewed · How we verify
NCT05829603: DHTP
Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects
Phase 1 trial testing Dimethyltryptamin (DMT) & Harmine in Healthy in 16 participants. Completed in 17 October 2023.
17 September 2023
Quick facts
| Lead sponsor | Reconnect Labs |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 16 |
| Start date | 5 May 2023 |
| Primary completion | 17 September 2023 |
| Estimated completion | 17 October 2023 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Dimethyltryptamin (DMT) & Harmine — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Reconnect Labs — full company profile →
Who can join
Adults 25 to 45, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety \& tolerability.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates fibrostenosis in Crohn's disease.
Ke BJ, Abdurahiman S, Biscu F, Zanella G, et al · · 2024 · cited 33× · PMID 39042469 · DOI 10.1172/jci173835
Verify or expand the search:
- PubMed search for NCT05829603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Reconnect Labs trials
Trials by the same sponsor.
- NCT06685965 — A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances · Phase 2 · recruiting
- NCT05979727 — Dose-finding PKPD Trial for RE02 in Healthy Subjects · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05829603 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Reconnect Labs
- Last refreshed: 2 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05829603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing